AZ's Brilique Approved As 60mg Continuation Therapy In Europe
This article was originally published in Scrip
Executive Summary
The European Commission has granted marketing authorization for AstraZeneca's Brilique (Brilinta; ticagrelor) at a new 60mg dose for the treatment of patients who have suffered a heart attack at least one year prior and are at high risk of developing a further atherothrombotic event.